Showing posts with label personalized medicine. Show all posts
Showing posts with label personalized medicine. Show all posts
Friday, May 1, 2015
Sloan Kettering CEO Summarizes State Of Cancer Knowledge, Developing Prevention And Treatment Strategies
The Future Of Cancer: Closer To A Cure by Craig Thompson. The Wall Street Journal. April 26, 2015
Monday, November 11, 2013
23andMe Genetic Analysis Firm Aims To Revolutionize The Healthcare Industry
Anne Wojcicki Is The Most Daring CEO In America. Fast Company. November 2013.
(1) According to a venture capitalist quoted in the article sales of genetic analysis kits is not the ultimate objective of 23andMe. Instead once the data from this analysis is obtained, 23andMe can become the _____________ of personalized health care.
(2) The genetic data gathered could be extremely valuable to ______________________.
(3) The company has collected data from 10,000 people with _______________, the world's largest ____________ community for genetic research.
(4) According to recent survey sited in the article ________% of internists from academic medical centers deemed their knowledge of genetics as "very/somewhat poor."
(5) A group of geneticists, lawyers, bioethics experts and social scientists are working on grants to develop a personal___________________ for ________________.
(1) According to a venture capitalist quoted in the article sales of genetic analysis kits is not the ultimate objective of 23andMe. Instead once the data from this analysis is obtained, 23andMe can become the _____________ of personalized health care.
(2) The genetic data gathered could be extremely valuable to ______________________.
(3) The company has collected data from 10,000 people with _______________, the world's largest ____________ community for genetic research.
(4) According to recent survey sited in the article ________% of internists from academic medical centers deemed their knowledge of genetics as "very/somewhat poor."
(5) A group of geneticists, lawyers, bioethics experts and social scientists are working on grants to develop a personal___________________ for ________________.
Tuesday, January 15, 2013
Pharmaceutical Strategy in the Age Of Personalized Medicine
A Strategist's Guide To Personalized Medicine by Avi Kularni and Nelia Padilla McGreevy. Strategy + Business. Winter 2013.
With the rising prevalence of chronic diseases, such as cancer, diabetes, and dementia, the need for specifically tailored drugs has increased. Since these chronic diseases impact patients in different ways according to their genetic makeup, pharmaceutical companies are shifting their business models. Shifting emphasis from blockbuster drugs aimed at a general population to niche drugs aimed at highly segmented target patient groups, these companies are shifting sales strategies, clinical trial methods, and their relationship to diagnostic tests.
With the rising prevalence of chronic diseases, such as cancer, diabetes, and dementia, the need for specifically tailored drugs has increased. Since these chronic diseases impact patients in different ways according to their genetic makeup, pharmaceutical companies are shifting their business models. Shifting emphasis from blockbuster drugs aimed at a general population to niche drugs aimed at highly segmented target patient groups, these companies are shifting sales strategies, clinical trial methods, and their relationship to diagnostic tests.
Sunday, November 4, 2012
Official Security Issues in The Biomedical Age
Hacking the President's DNA by Andrew Hessel, Marc Goodman, and Steven Kotler. The Atlantic Magazine. November 2012.
An age of personalized medicine based upon the design of cures based upon personal genetic code offers many possibilities for health and healing. The article explores the dark side of the biotechnology that this age is creating. Security issues for officials and others are discussed.
An age of personalized medicine based upon the design of cures based upon personal genetic code offers many possibilities for health and healing. The article explores the dark side of the biotechnology that this age is creating. Security issues for officials and others are discussed.
Subscribe to:
Posts (Atom)